- Home
- C vs TMO Comparison
C vs TMO Comparison
Compare C & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | C | TMO |
|---|---|---|
| Founded | 1812 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.0B | 216.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | C | TMO |
|---|---|---|
| Price | $120.58 | $579.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | $109.93 | ★ $631.00 |
| AVG Volume (30 Days) | ★ 13.8M | 1.5M |
| Earning Date | 01-14-2026 | 01-29-2026 |
| Dividend Yield | ★ 1.99% | 0.30% |
| EPS Growth | ★ 103.93 | 8.54 |
| EPS | 7.10 | ★ 17.32 |
| Revenue | ★ $75,384,000,000.00 | $43,736,000,000.00 |
| Revenue This Year | $23.05 | $4.33 |
| Revenue Next Year | $3.20 | $4.98 |
| P/E Ratio | ★ $16.95 | $33.54 |
| Revenue Growth | ★ 9.24 | 3.22 |
| 52 Week Low | $55.51 | $385.46 |
| 52 Week High | $122.84 | $610.97 |
Technical Indicators
Market Signals| Indicator | C | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 77.91 | 56.07 |
| Support Level | $110.55 | $554.53 |
| Resistance Level | $122.84 | $580.56 |
| Average True Range (ATR) | 2.42 | 9.83 |
| MACD | 0.89 | 0.22 |
| Stochastic Oscillator | 84.71 | 98.36 |
Price Performance
Historical ComparisonAbout C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).